GLOBAL HEALTH | GLOBAL PARTNERSHIPS | GLOBAL IMPACT

Research

Photo for ACTIVE I

ACTIVE I

Official Title

Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events

Status

Completed

Overview

To determine the efficacy (superiority) of Irbesartan compared to Placebo would reduce the risk of vascular events such as heart attack, stroke, non-cerebral thromboembolic event and death in patients with Atrial Fibrillation (AF) and with at least one major risk of vascular events.

Study Design

Randomized, double-blind, efficacy study, placebo controlled, factorial design superiority trial.

Primary Endpoint

Composite outcome of stroke, myocardial infarction, vascular death or hospitalization for heart failure

Number of Patients

9015

Number of Sites

625

Number of Countries

33

Study Period

2003–2009

Principal Investigator

Stuart Connolly

Program Manager

Susan Chrolavicius

Research Coordinator

Heather Beresh, Laura Bonilla

Key Publications

  • ACTIVE I Investigators, Yusuf S, Healey JS, Pogue J, Chrolavicius S, Flather M, Hart RG, Hohnloser SH, Joyner CD, Pfeffer MA, Connolly SJ. Irbesartan in patients with atrial fibrillation. N Engl J Med. 2011 Mar 10;364(10):928-38. doi: 10.1056/NEJMoa1008816.